[Actovegin treatment of duodenal ulcer associated with ischemic heart disease and diabetes mellitus]

Klin Med (Mosk). 2000;78(6):24-8.
[Article in Russian]

Abstract

Actovegin, a deproteinized hemoderivative, was used to correct bioenergetic defects of duodenal mucosa, to reduce inflammatory-cell infiltration, to stimulate blood supply of patients with duodenal ulcer associated with ischemic heart disease or diabetes mellitus. As shown by the results obtained in 194 patients (119 males and 75 females), adjuvant actovegin in patients with duodenal ulcer associated with ischemic heart disease and diabetes mellitus stimulates the ulcer healing, prolongs the recurrence-free interval. It can be used both in outpatient departments and specialized hospitals.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Adult
  • Anti-Ulcer Agents / administration & dosage
  • Anti-Ulcer Agents / therapeutic use*
  • Biological Transport / drug effects
  • Diabetes Complications*
  • Diabetes Mellitus / metabolism
  • Drug Administration Routes
  • Duodenal Ulcer / complications
  • Duodenal Ulcer / diagnosis
  • Duodenal Ulcer / drug therapy*
  • Duodenal Ulcer / metabolism
  • Duodenoscopy
  • Female
  • Glucose / metabolism
  • Heme / administration & dosage
  • Heme / analogs & derivatives*
  • Heme / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Myocardial Ischemia / complications*
  • Myocardial Ischemia / metabolism
  • Oxygen Consumption / drug effects
  • Secondary Prevention
  • Treatment Outcome

Substances

  • Anti-Ulcer Agents
  • Heme
  • Actovegin
  • Adenosine Triphosphate
  • Glucose